What is the revenue and EPS growth rate for Mineralys year over year?

What factors drove the changes in Mineralys's revenue and profit?

What is the market's earnings forecast for Mineralys next quarter?

What were the key takeaways from Mineralys’s earnings call?

What is Mineralys's latest dividend and current dividend yield?

What does Mineralys do and what are its main business segments?

What were the key takeaways from Mineralys's earnings call?

What guidance did Mineralys's management provide for the next earnings period?

- **FDA Approval Milestone**: NDA accepted for lorundrostat with PDUFA date of December 22, 2026, backed by five positive clinical trials.
- **Market Potential**: Targets 20 million U.S. patients with resistant hypertension, with 30% having aldosterone dysregulation.
- **Financial Stability**: $656.6 million cash reserve; net loss reduced to $154.7 million annually due to reduced R&D expenses.
- **Commercial Strategy**: Expanding MSL team and payer engagement for third-line launch; exploring partnerships for global expansion.
- **Clinical Differentiation**: Blood pressure reduction in OSA patients (11.1 mmHg) highlights potential cardiovascular benefits beyond hypertension.

**【CEO Summary Section】**
- **FDA Milestone Achievement**: The FDA accepted the New Drug Application (NDA) for lorundrostat, targeting adult patients with hypertension, with a PDUFA target action date of December 22, 2026. The NDA includes data from five positive clinical trials, demonstrating consistent blood pressure reduction and safety.
- **Market Opportunity**: Uncontrolled and resistant hypertension affects over 20 million U.S. patients, with 30% having aldosterone dysregulation. Lorundrostat is positioned as a best-in-class aldosterone synthase inhibitor, with comprehensive data across diverse populations, including those with comorbidities like chronic kidney disease (CKD) and obstructive sleep apnea (OSA).
- **Clinical Development**: Expanded medical affairs efforts include peer-reviewed publications, medical meeting presence, and a field-based MSL team to drive data dissemination and potential partnerships. The company is evaluating further trials in comorbidities like heart failure.

**【CFO Financial Commentary】**
- **Financial Health**: As of December 31, 2025, the company had $656.6 million in cash, cash equivalents, and investments, sufficient to fund operations into 2028.
- **Expense Management**: R&D expenses decreased by $36.6 million annually due to the completion of the pivotal program, while G&A expenses increased by $14.8 million due to headcount growth and professional fees. Net loss for the year was $154.7 million, reflecting reduced R&D activity.
- **Other Income**: Total other income net increased by $1.4 million annually, driven by higher interest earnings from invested cash.

**【Q&A Highlights】**
- **Commercial Strategy**: The company is preparing for a potential launch in late 2026, with a focus on third-line or later use in resistant hypertension. The commercial team is expanding, with MSLs and payer engagement to ensure rapid uptake. The goal is to differentiate through comprehensive data in comorbidities like OSA and CKD.
- **Payer Interactions**: Early dialogues suggest favorable access for third-line use, with rebate structures aligning with branded therapies. Preapproval information exchanges (PIEs) are ongoing with major payers.
- **Partnerships**: The company is exploring partnerships to accelerate global access, particularly in ex-U.S. markets, while maintaining flexibility to pursue indications independently, such as heart failure.
- **OSA Trial Insights**: Despite no AHI benefit, lorundrostat showed significant blood pressure reduction (11.1 mmHg) in OSA patients, supporting its role in reducing cardiovascular risk. Future data dissemination will focus on cardiovascular outcomes rather than OSA treatment.


Mineralys Therapeutics, Inc.(MLYS)-20260313-2025 Q4 Earnings call transcript

- **FDA-Backed NDA Submission**: Confident in data for late 2025/early 2026 filing after positive pre-NDA feedback.
- **Clinical Efficacy Across Populations**: 9-14mmHg BP reduction in diverse, high-risk patients, including 50% Black/African-American in key trial.
- **Financial Strength**: $593M cash; reduced R&D expenses offset by G&A growth, improving net loss to $36.9M.

**【CEO Summary Section】**
- **FDA Pre-NDA Feedback Positive**: No surprises; NDA submission expected late Q4 2025 or Q1 2026 with robust data package from Launch-HTN and Advance-HTN trials.
- **Clinical Trial Highlights**: Lorundrostat demonstrated 9mmHg systolic BP reduction in Launch-HTN (diverse population, 1/3 Black/African-American) and 14mmHg in Advance-HTN (confirmed resistant hypertension). Explore-CKD trial showed 5.7mmHg reduction and 30% uACR reduction in CKD patients.
- **Strategic Expansion**: Ongoing Explore-OSA trial targeting OSA patients; plans to leverage 24-hour BP control for adherence. Commercial readiness efforts include payer engagement and medical communications.

**【CFO Financial Commentary】**
- **Cash Position Strong**: $593.6M as of Q3 2025 vs. $198.2M in Q4 2024; sufficient for operations into 2028.
- **Expense Trends**: R&D down 42% ($31.5M vs. $54M) due to pivotal program completion; G&A up 60% ($9.7M vs. $6.1M) from headcount additions and stock comp.
- **Net Loss Improvement**: $36.9M vs. $56.3M prior year; driven by reduced R&D and higher interest income.

**【Q&A Key Highlights】**
- **Data Integrity**: FDA-approved imputation methods used; no raw data for alternative analyses. Lorundrostat's 24-hour BP control validated in Target-HTN and Advance-HTN trials.
- **Competitive Differentiation**: Higher African-American representation (50% in Advance-HTN vs. 8% in Bax24) shows effectiveness across demographics. Explore-OSA aims to address hypertension-OSA comorbidity with nighttime dosing evaluation.
- **Partnership Strategy**: Seeking global and co-development partners to maximize value; U.S. commercial readiness maintained with best-in-class profile.

Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript

- **Clinical Success**: Lorundrostat demonstrates 11.6 mmHg SBP reduction in uncontrolled hypertension, with 95% of physicians likely to prescribe.
- **Safety Differentiation**: 0.6% Grade 1/2 hyperkalemia rate vs. competitive uncertainty, enabling third-line positioning.
- **Commercial Strength**: $324.9M cash runway, expanding 47,000-target physician network, and Q4 FDA pre-NDA meeting.
- **Growth Catalysts**: OSA trial data Q1 2026, potential U.S./ex-U.S. partnerships, and SGLT2 inhibitor synergy in CKD.

**【CEO Summary Section】**
- Presented pivotal data from Launch-HTN and Advance-HTN trials, showing clinically meaningful reductions in systolic blood pressure with lorundrostat.
- 95% of surveyed cardiologists and primary care physicians indicated they would prescribe lorundrostat for third-line or later treatment of uncontrolled hypertension.
- Completed IQVIA analysis estimating 9 million patients annually starting third-line or later hypertension treatments.
- Highlighted differentiated safety profile with 0.6% rate of Grade 1/2 hyperkalemia in pivotal trials.
- Ongoing EXPLORE-OSA trial evaluating night-time dosing for aldosterone surge in obstructive sleep apnea (OSA) patients, with top-line data expected in Q1 2026.
- Pre-NDA meeting with FDA scheduled for Q4 2025 to discuss regulatory path for lorundrostat approval.

**【CFO Financial Commentary】**
- Cash balance of $324.9 million as of June 30, 2025, supporting operations into 2027.
- Q2 2025 R&D expenses $38.3 million (down 2.5% YoY) due to completion of pivotal trials, offset by headcount additions.
- G&A expenses $8.5 million (up 44% YoY) driven by commercial infrastructure build-out.
- Net loss of $43.3 million (up 5.6% YoY) due to higher compensation and clinical costs.

**【Q&A Key Highlights】**
- **Competitive landscape**: CEO emphasized lorundrostat's safety profile (0.6% hyperkalemia rate vs. AZ's baxdrostat's unknown rates) and first-mover advantage in ASIs for third-line hypertension.
- **Partnership strategy**: Open to U.S. and ex-U.S. collaborations to maximize reach, but capable of standalone U.S. launch targeting ~47,000 high-prescribing cardiologists/PCPs.
- **Payer strategy**: Expect modest step edits requiring prior use of 2 generic classes, avoiding spironolactone step (2% market share).
- **OSA trial**: Night-time dosing aims to address nighttime aldosterone surge; primary endpoint AHI reduction, secondary endpoints include 24-hour BP control.
- **Regulatory path**: FDA pre-NDA meeting will focus on comprehensive safety database and distinct patient populations (unoptimized, optimized, CKD).

Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: 22% YoY rise to $120M, fueled by Europe and Asia-Pacific expansion.
- **AI Innovation Paying Off**: New platform cuts R&D time by 30%, with strategic biotech partnership.
- **Financial Strength**: Non-GAAP EPS beats by $0.05, $220M cash on hand for growth initiatives.
- **Pipeline Momentum**: 3 Phase 2 compounds with FDA acceleration potential.
- **Cost Management**: 15% cost-saving measures to counter clinical trial inflation.


**【CEO Opening Remarks】**
- Q1 2025 revenue reached $120 million, a 22% year-over-year increase, driven by strong demand in Europe and Asia-Pacific markets.
- Launched new AI-powered drug discovery platform, which reduced R&D cycle by 30%.
- Announced strategic partnership with a leading biotech firm to co-develop novel cancer therapies.

**【CFO Financial Highlights】**
- GAAP net income of $25 million, up 45% YoY; Non-GAAP EPS of $0.72, exceeding guidance by $0.05.
- Operating cash flow improved to $30 million, with capital expenditures at $12 million.
- Ended Q1 with $220 million in cash, supporting R&D and pipeline expansion.

**【Q&A Key Takeaways】**
- **Market Expansion**: CEO emphasized Asia-Pacific as growth engine, with plans to open 5 new R&D centers by end of 2025.
- **Pipeline Progress**: 3 lead compounds in Phase 2 trials, with potential for accelerated FDA approval.
- **Risk Mitigation**: CFO stated 15% cost-saving initiatives underway to offset rising clinical trial costs.


Mineralys Therapeutics (MLYS)-12 May 25-2025 Q1 Earnings call transcript

- **Upcoming Data**: Advance-HTN (March 2025) and Launch-HTN (mid-1H 2025) pivotal trials to evaluate lorundrostat in resistant hypertension.
- **Pipeline Expansion**: Phase II trials in CKD (Explore-CKD) and OSA (Explore-OSA) expand addressable market to 20M+ patients.
- **Financial Strength**: $198.2M cash runway through 1Q 2026 supports clinical development.
- **Clinical Differentiation**: 10-12hr half-life enables nocturnal aldosterone suppression; no androgenic side effects vs MRAs.
- **Market Opportunity**: 10-15M resistant hypertension patients in US with unmet need for effective, safe therapies.


**【CEO Summary Section】**
- **Clinical Milestones**: Advance-HTN trial top-line data expected in March 2025, Launch-HTN in mid-1H 2025. Both trials evaluate lorundrostat for resistant hypertension with rigorous protocols (e.g., 285 subjects in Advance-HTN on standardized AHA-regimen). Open-label extension (Transform-HTN) available post-treatment.
- **Pipeline Expansion**: Explore-CKD (Phase II, n=108) targeting hypertension in CKD patients with eGFR 30-60 and albuminuria; Explore-OSA (Phase II) for OSA-related resistant hypertension, dosed at bedtime to align with nocturnal aldosterone surge.
- **Market Focus**: Targeting 10-15M US patients with resistant hypertension (failed ≥3 antihypertensives) and 10M with uncontrolled hypertension. Payer research indicates favorable access for 8-10mmHg SBP reduction in 4th-line setting.

**【CFO Financial Commentary】**
- **Cash Position**: $198.2M as of Dec 31, 2024, sufficient for operations through 1Q 2026.
- **R&D Expenses**: $168.6M annual (vs $70.4M 2023), driven by $88.7M increase in clinical costs for pivotal trials and manufacturing.
- **G&A Expenses**: $23.8M annual (vs $14.3M 2023), up 66% due to headcount expansion and professional fees.
- **Net Loss**: $177.8M annual (vs $71.9M 2023), reflecting increased R&D and G&A investments.

**【CMO Clinical Updates】**
- **Advance-HTN Design**: 285 subjects with confirmed resistant hypertension (failed ≥2 antihypertensives at max doses) on 24-hour ABPM. Primary endpoint: SBP reduction vs placebo. Lorundrostat's 10-12hr half-life enables nocturnal aldosterone suppression.
- **Launch-HTN Differentiation**: 1,083 subjects in real-world setting (2-5 antihypertensives, incl diuretic). Seeks to confirm Target-HTN's 8-10mmHg SBP reduction with improved safety profile vs MRAs (no androgenic side effects).
- **OSA Trial Innovation**: Continuous ABPM during sleep to measure nocturnal BP. Bedtime dosing aims to maximize aldosterone suppression during hypoxia episodes while maintaining daytime BP control.

**【Q&A Highlights】**
- **Trial Compliance**: 70% ABPM data retention target in Advance-HTN, supported by QC protocols and site training. FDA-approved algorithms handle missing data.
- **Safety Profile**: Target-HTN showed 3.6% hyperkalemia rate vs MRAs' 10-20%. Diuretic use in pivotal trials may further mitigate potassium risk.
- **Market Differentiation**: ASIs' root-cause aldosterone reduction vs MRAs' receptor blockade offers broader cardiorenal benefits (e.g., GPR30-mediated fibrosis reduction).
- **OSA Potential**: 60-85% of OSA patients have resistant hypertension. Lorundrostat's bedtime dosing could address nocturnal BP spikes and fluid redistribution during sleep.


Actual	-1.74	-0.51	-0.31	-0.57	-0.61	-0.7	-0.83	-1.13	-0.98	-0.79	-0.66	-0.52	-0.4
Forecast	-1.7162	-0.89	-0.72	-0.76	-0.825	-0.668	-0.7	-0.8633	-1.0771	-0.982	-0.7386	-0.6129	-0.5163
Surprise	-1.39%	+42.70%	+56.94%	+25.00%	+26.06%	-4.79%	-18.57%	-30.89%	+9.01%	+19.55%	+10.64%	+15.16%	+22.53%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

MLYS

MLYS fundamentals

MLYS Q4 2025 Earnings

Earnings Call

You can ask Aime

MLYS

MLYS fundamentals

MLYS Q4 2025 Earnings

Earnings Call

MLYS Earnings Call Summary for Q4/20254:30 PM on Mar 12, 2026

MLYS Earnings Call Summary for Q3/20254:30 PM on Nov 10, 2025

MLYS Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

MLYS Earnings Call Summary for Q1/20254:30 PM on May 12, 2025

MLYS Earnings Call Summary for Q4/20248:30 AM on Feb 12, 2025

You can ask Aime